Additionally, semaglutide demonstrated neuroprotective benefits to the CNS leading to enhancement to cell survival, decreased M1-like microglia numbers, and reduced interleukin-6 and TNF-α levels in different brain areas in obesity (Tamayo-Trujillo et al. 2024). Here, IL6 is linked to obesity due to melanocortin 4 receptor deficiency.